UNSPSC 51272605: Phenoperidine hydrochloride

This classification denotes an opioid and analgesic agent C23H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D9C1OK7KZ, chemically known as isonipecotic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester, hydrochloride, but more generally known as phenoperidine hydrochloride, which bears US NIH Compound Identifier 19260. European Medicines Agency schedules Phenoperidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03758MIG.

Most nations, for tariff and trade purposes, schedule phenoperidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PHENOPERIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCOC(=O)C1(CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.

UNSPSC 51272605 Phenoperidine hydrochloride (Commodity) shows minimal recent state and local procurement activity aligned with its nominal scope. The three most recent opportunities tagged to this code span pharmaceutical procurement broadly — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which center on phenoperidine hydrochloride as a specific active ingredient. State and local procurement records do not reflect demand for phenoperidine hydrochloride itself as a line item in current solicitations.

Recent opportunities in the broader pharmaceutical-procurement space show activity from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Seminole County issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response due July 26, 2023). Texas HHS issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs. MMCAP issued an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, spanning Minnesota, Oregon, and participating state and local facilities. The code does not reflect current state and local demand for phenoperidine hydrochloride as a procurement line item.